MG-S-2525 / Metagone Biotech - LARVOL DELTA

“Unlisted stocks“ Xinlisheng’s Idiopathic Pulmonary Fibrosis Phase II Clinical TFDA Approval [Google translation] (Yahoo News) - "Xinlisheng (6824) Subsidiary Shuo De Biotechnology Co., Ltd....received approval from the Ministry of Health and Welfare (TFDA) to start the Phase II human trial of MG-S-2525 idiopathic pulmonary fibrosis at National Taiwan University Hospital. The Phase II human trial…will accept 18 qualified subjects…The trial is expected to be completed in the first half of 2022..."

New P2 trial • Trial completion date • Idiopathic Pulmonary Fibrosis • Respiratory Diseases

To Determine Safety and Tolerability of MG-S-2525 and to Evaluate Its PK Profile in Healthy Volunteers (clinicaltrials.gov) - P1; N=81; Completed; Sponsor: Metagone Biotech Inc.; Recruiting ➔ Completed; Trial completion date: Dec 2021 ➔ Feb 2020; Trial primary completion date: Dec 2021 ➔ Dec 2019

Clinical • Trial completion • Trial completion date • Trial primary completion date • Fibrosis • Idiopathic Pulmonary Fibrosis • Immunology • Respiratory Diseases

To Determine Safety and Tolerability of MG-S-2525 and to Evaluate Its PK Profile in Healthy Volunteers (clinicaltrials.gov) - P1; N=72; Recruiting; Sponsor: Metagone Biotech Inc.; Not yet recruiting ➔ Recruiting; Trial completion date: Dec 2019 ➔ Dec 2021; Initiation date: Sep 2018 ➔ Feb 2019; Trial primary completion date: Jun 2019 ➔ Dec 2021

Clinical • Enrollment open • Trial completion date • Trial initiation date • Trial primary completion date